Sandbox/00015

Jump to navigation Jump to search



Pathogen-Based Therapy — Bacteria Adapted from Lancet. 2010;375(9717):846-55.[1] and Clin Microbiol Rev. 2002;15(4):527-44.[2]

▸ Click on the following categories to expand treatment regimens.

Bacteria

  ▸  Bacteroides fragilis

  ▸  Brucella melitensis

  ▸  Enterococcus spp.

  ▸  Escherichia coli

  ▸  Haemophilus influenzae

  ▸  Morganella morganii

  ▸  Neisseria gonorrhoeae

  ▸  Proteus mirabilis

  ▸  Proteus vulgaris, Proteus rettgeri

  ▸  Pseudomonas aeruginosa

  ▸  Serratia marcescens

  ▸  Staphylococcus aureus

  ▸  Staphylococcus epidermidis

  ▸  Streptococcus agalactiae

  ▸  Streptococcus pyogenes

  ▸  Tropheryma whipplei

Mycobacteria

  ▸  Mycobacterium tuberculosis

Spirochetes

  ▸  Borrelia burgdorferi

  ▸  Treponema pallidum

Bacteroides fragilis
Preferred Regimen
▸ Clindamycin 900 mg IV/IM q8h
OR
▸ Metronidazole 500 mg IV q8h
Alternative Regimen
▸ Ampicillin-Sulbactam 3 g IV q6h
OR
▸ Ticarcillin-Clavulanate 3.1 g IV q4–6h
Morganella morganii
Preferred Regimen
▸ Cefotaxime 2 g IV q6h
OR
▸ Imipenem 500 mg IV q6h
OR
▸ Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
▸ Gentamicin 3–5 mg/kg/day IV q6–8h
OR
▸ Ticarcillin-Clavulanate 3.1 g IV q4–6h
Proteus vulgaris, Proteus rettgeri
Preferred Regimen
▸ Cefotaxime 2 g IV q6h
OR
▸ Imipenem 500 mg IV q6h
OR
▸ Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
▸ Gentamicin 3–5 mg/kg/day IV q6–8h
OR
▸ Ticarcillin-Clavulanate 3.1 g IV q4–6h
Serratia marcescens
Preferred Regimen
▸ Cefotaxime 2 g IV q6h
Alternative Regimen
▸ Levofloxacin 500 mg IV/PO q24h
OR
▸ Gentamicin 3–5 mg/kg/day IV q6–8h
OR
▸ Imipenem 500 mg IV q6h
Brucella melitensis
Preferred Regimen
▸ Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
▸ Streptomycin 15 mg/kg IM qd for 2–3 weeks
OR
▸ Rifampin 600–900 mg qd for ≥6 weeks
Alternative Regimen
▸ Doxycycline 100 mg PO bid for ≥6 weeks
PLUS
▸ Gentamicin 5 mg/kg IV qd for 7 days
Adapted from PLoS Med. 2007;4(12):e317.[3] and Lancet Infect Dis. 2007;7(12):775-86.[4] and Cochrane Database Syst Rev. 2012;10:CD007179.[5]
Methicillin-Sensitive S. aureus
Preferred Regimen
▸ Nafcillin 2 g IV q6h
OR
▸ Clindamycin 900 mg IV q8h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h
OR
▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. aureus (Adult)
Preferred Regimen
▸ Vancomycin 15–20 mg/kg IV q8–12h
OR
▸ Daptomycin 6 mg/kg IV q24h
OR
▸ Linezolid 600 mg PO/IV q12h
Alternative Regimen 1
▸ TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component)
PLUS
▸ Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
▸ Clindamycin 600 mg IV/IM q8h
Methicillin-Resistant S. aureus (Pediatric)
Preferred Regimen
▸ Vancomycin 15 mg/kg IV q6h
OR
▸ Clindamycin 10 mg/kg PO/IV q6h (or 13 mg/kg PO/IV q8h)
Alternative Regimen
▸ Daptomycin 6–10 mg/kg IV q24h
OR
▸ Linezolid 10 mg/kg PO/IV q8h (Maximum: 600 mg/dose)
Adapted from Clin Infect Dis. 2011;52(3):e18-55.[6]
Methicillin-Sensitive S. epidermidis
Preferred Regimen
▸ Nafcillin 2 g IV q6h
OR
▸ Clindamycin 900 mg IV/IM q8h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h
OR
▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h)
Methicillin-Resistant S. epidermidis
Preferred Regimen
▸ Vancomycin 500 mg IV q6h (or 1 g IV q12h)
OR
▸ Linezolid 600 mg IV q12h
Alternative Regimen 1
▸ TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component)
OR
▸ Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h
PLUS
▸ Rifampin 300–600 mg PO/IV q12h
Alternative Regimen 2
▸ Clindamycin 900 mg IV/IM q8h
Streptococcus agalactiae
Preferred Regimen
▸ Penicillin G 2 MU IV/IM q4h
OR
▸ Ampicillin 2 g IV q6h
Alternative Regimen
▸ Clindamycin 600–1200 mg/day IV/IM q6–12h
OR
▸ Cefazolin 0.25–1 g IV/IM q6–8h
Streptococcus pyogenes
Preferred Regimen
▸ Penicillin G 2 MU IV/IM q4h
OR
▸ Ampicillin 2 g IV q6h
Alternative Regimen
▸ Clindamycin 600–1200 mg/day IV/IM q6–12h
OR
▸ Cefazolin 0.25–1 g IV/IM q6–8h
Escherichia coli
Preferred Regimen
▸ Ampicillin-Sulbactam 3 g IV q6h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h
OR
▸ Levofloxacin 500–750 mg IV/PO q24h
OR
▸ Gentamicin 3–5 mg/kg/day IV q6–8h
OR
▸ TMP-SMX 8–10 mg/kg/day IV/PO q6–12h (TMP component)
Pseudomonas aeruginosa
Preferred Regimen
▸ Cefepime 2 g IV q12h
OR
▸ Piperacillin 3–4 g IV q4–6h
OR
▸ Imipenem 500 mg IV q6h
Alternative Regimen
▸ Ticarcillin-Clavulanate 3.1 g IV q4–6h
OR
▸ Tobramycin 3-5 mg/kg/day IV q6–8h
OR
▸ Amikacin 15 mg/kg/day IV/IM q8–12h
OR
▸ Ciprofloxacin 400 mg IV q8–12h
Neisseria gonorrhoeae
Preferred Regimen
▸ Ceftriaxone 2 g IV q24h
OR
▸ Cefotaxime 1 g IV q8h
Alternative Regimen
▸ Levofloxacin 500 mg IV/PO q24h
OR
▸ Ampicillin 2 g IV q6h
Haemophilus influenzae
Preferred Regimen
▸ Amoxicillin-clavulanate 875/125 mg PO q12h
OR
▸ Cefprozil 500 mg PO q12h
OR
▸ Cefuroxime 500 mg PO q12h
OR
▸ Cefdinir 600 mg PO q24h
Alternative Regimen
▸ Levofloxacin 750 mg IV/PO q24h
OR
▸ Moxifloxacin 400 mg IV/PO q24h
OR
▸ Clarithromycin 500 mg PO q12h
Mycobacterium tuberculosis
Intensive Phase
▸ Isoniazid 5mg/kg PO q24h for 2 months
OR
▸ Isoniazid 10 mg/kg PO 3 times per week × 2 months
PLUS
▸ Rifampicin 10 mg/kg PO q24h for 2 months
OR
▸ Rifampicin 10 mg/kg PO 3 times per week × 2 months
PLUS
▸ Pyrazinamide 25mg/kg PO q24h for 2 months
OR
▸ Pyrazinamide 35 mg/kg PO 3 times per week × 2 months
PLUS
▸ Ethambutol 15mg/kg PO q24h for 2 months
Continuation Phase
▸ Isoniazid 5mg/kg PO for 4-7 months
OR
▸ Isoniazid 10 mg/kg PO 3 times per week × 4-7 months
PLUS
▸ Rifampicin 10 mg/kg PO q24h for 4-7 months
OR
▸ Rifampicin 10 mg/kg PO 3 times per week for 4-7 months
Adapted from Treatment of Tuberculosis: Guidelines.[7]
Borrelia burgdorferi
Preferred Regimen
▸ Amoxicillin 500 mg q8h for 28 days
OR
▸ Doxycycline 100 mg q12h for 28 days
OR
▸ Cefuroxime 500 mg q12h for 28 days
Alternative Regimen
▸ Azithromycin 500 mg PO q24h for 7–10 days
OR
▸ Clarithromycin 500 mg PO q12h for 14–21 days
OR
▸ Erythromycin 500 mg PO q6h for 14–21 days
Adapted from IDSA Guidelines: The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: [8]
Treponema pallidum
Preferred Regimen
▸ Penicillin G 2.4 MU IM single dose
Alternative Regimen
▸ Doxycycline 100 mg PO q12h x 14 days
OR
▸ Tetracycline 500 mg PO q6h x 14 days
OR
▸ Ceftriaxone 1 g IM/IV q24h x 10 -14 days
Adapted from MMWR Recomm Rep. 2006;55(RR-11):1-94[9]
Tropheryma whipplei
Preferred Regimen
▸ Penicillin G 2 MU IV q4h for 2 weeks
PLUS
▸ Streptomycin 1 g IM/IV q24h for 2 weeks
FOLLOWED BY
▸ Trimethoprim/Sulfamethoxazole 160mg/800mg PO q24h for 1 year
Alternative Regimen
▸ Ceftriaxone 2 g IV q24h
FOLLOWED BY
▸ Trimethoprim/Sulfamethoxazole 160mg/800mg PO q24h for 1 year
Adapted from N Engl J Med 2007; 356:55-66 [10]
Enterococcus spp.
Preferred Regimen
▸ Ampicillin 2 g IV q6h
OR
▸ Vancomycin 1 g IV q12h
Alternative Regimen
▸ Ampicillin-Sulbactam 3 g IV q6h
OR
▸ Linezolid 600 mg PO/IV q12h
Proteus mirabilis
Preferred Regimen
▸ Ampicillin 2 g IV q6h
OR
▸ Levofloxacin 500 mg IV/PO q24h
Alternative Regimen
▸ Cefazolin 0.25–1 g IV/IM q6–8h
OR
▸ TMP-SMX 8–10 mg/kg/day IV/PO q6–12h (TMP component)
OR
▸ Gentamicin 3–5 mg/kg/day IV q6–8h

References

  1. ↑ Mathews CJ, Weston VC, Jones A, Field M, Coakley G (2010). "Bacterial septic arthritis in adults". Lancet. 375 (9717): 846–55. doi:10.1016/S0140-6736(09)61595-6. PMID 20206778.
  2. ↑ Shirtliff ME, Mader JT (2002). "Acute septic arthritis". Clin Microbiol Rev. 15 (4): 527–44. PMC 126863. PMID 12364368.
  3. ↑ Ariza, Javier; Bosilkovski, Mile; Cascio, Antonio; Colmenero, Juan D.; Corbel, Michael J.; Falagas, Matthew E.; Memish, Ziad A.; Roushan, Mohammad Reza Hasanjani; Rubinstein, Ethan; Sipsas, Nikolaos V.; Solera, Javier; Young, Edward J.; Pappas, Georgios (2007). "Perspectives for the Treatment of Brucellosis in the 21st Century: The Ioannina Recommendations". PLoS Medicine. 4 (12): e317. doi:10.1371/journal.pmed.0040317. ISSN 1549-1277.
  4. ↑ Franco MP, Mulder M, Gilman RH, Smits HL (2007). "Human brucellosis". Lancet Infect Dis. 7 (12): 775–86. doi:10.1016/S1473-3099(07)70286-4. PMID 18045560.
  5. ↑ Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P (2012). "Antibiotics for treating human brucellosis". Cochrane Database Syst Rev. 10: CD007179. doi:10.1002/14651858.CD007179.pub2. PMID 23076931.
  6. ↑ Liu, C.; Bayer, A.; Cosgrove, S. E.; Daum, R. S.; Fridkin, S. K.; Gorwitz, R. J.; Kaplan, S. L.; Karchmer, A. W.; Levine, D. P.; Murray, B. E.; Rybak, M. J.; Talan, D. A.; Chambers, H. F. (2011). "Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children". Clinical Infectious Diseases. 52 (3): e18–e55. doi:10.1093/cid/ciq146. ISSN 1058-4838.
  7. ↑ Treatment of tuberculosis : guidelin. Geneva: World Health Organization. 2010. ISBN 978-92-4-154783-3.
  8. ↑ . doi:10.1086/522848. Missing or empty |title= (help)
  9. ↑ "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5511a1.htm". Retrieved 19 May 2014. External link in |title= (help)
  10. ↑ Fenollar, Florence; Puéchal, Xavier; Raoult, Didier (2007). "Whipple's Disease". New England Journal of Medicine. 356 (1): 55–66. doi:10.1056/NEJMra062477. ISSN 0028-4793.